Tags

Type your tag names separated by a space and hit enter

Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
J Clin Oncol. 2008 Aug 01; 26(22):3727-34.JC

Abstract

PURPOSE

The clinicopathologic importance of a second estrogen receptor (ER), ER-beta, in breast cancers has been intensely studied; however, there is still no real consensus regarding the clinical utility of an ER-beta assay, probably because of the lack of standardized methodology, the presence of several ER-beta isotypes (ER-beta1-5, and so on), and, more importantly, the lack of convincing data on whether the ER-beta status provides clinically useful information over what is already provided by the traditional ER-alpha/progesterone receptor (PR) assay. A large and systematic study is needed to address these important issues.

PATIENTS AND METHODS

Archival materials of 442 invasive breast cancers from women treated with adjuvant tamoxifen monotherapy and with a long follow-up period (median, 11.1 years) were subjected to immunohistochemical study using three commercially available anti-ER-beta antibodies that detect ER-beta1-3 (ER-betaN), ER-beta1, and ER-betacx (ER-beta2).

RESULTS

Positive staining for ER-betaN or ER-beta1 was associated with significantly better survival. By contrast, ER-betacx status did not influence survival. In multivariate analysis, ER-beta1 status emerged as an independent predictor of recurrence and mortality. ER-beta1 status was significantly associated with survival in postmenopausal, but not premenopausal, women. Importantly, ER-beta1 positivity was associated with significantly better survival in patients with ER-alpha-negative/PR-negative or ER-alpha-negative/PR-negative/human epidermal growth factor receptor 2-negative (triple-negative) tumors, which are widely believed to be hormone unresponsive, have poor prognosis, and require chemotherapy.

CONCLUSION

Immunohistochemical examination of ER-beta1 in addition to ER-alpha and PR is clinically important in patients with breast cancer treated with tamoxifen monotherapy. Further studies are needed to confirm our findings.

Authors+Show Affiliations

Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. nhonma@tmig.or.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18669459

Citation

Honma, Naoko, et al. "Clinical Importance of Estrogen Receptor-beta Evaluation in Breast Cancer Patients Treated With Adjuvant Tamoxifen Therapy." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 26, no. 22, 2008, pp. 3727-34.
Honma N, Horii R, Iwase T, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol. 2008;26(22):3727-34.
Honma, N., Horii, R., Iwase, T., Saji, S., Younes, M., Takubo, K., Matsuura, M., Ito, Y., Akiyama, F., & Sakamoto, G. (2008). Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 26(22), 3727-34. https://doi.org/10.1200/JCO.2007.14.2968
Honma N, et al. Clinical Importance of Estrogen Receptor-beta Evaluation in Breast Cancer Patients Treated With Adjuvant Tamoxifen Therapy. J Clin Oncol. 2008 Aug 1;26(22):3727-34. PubMed PMID: 18669459.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. AU - Honma,Naoko, AU - Horii,Rie, AU - Iwase,Takuji, AU - Saji,Shigehira, AU - Younes,Mamoun, AU - Takubo,Kaiyo, AU - Matsuura,Masaaki, AU - Ito,Yoshinori, AU - Akiyama,Futoshi, AU - Sakamoto,Goi, PY - 2008/8/2/pubmed PY - 2008/8/15/medline PY - 2008/8/2/entrez SP - 3727 EP - 34 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J Clin Oncol VL - 26 IS - 22 N2 - PURPOSE: The clinicopathologic importance of a second estrogen receptor (ER), ER-beta, in breast cancers has been intensely studied; however, there is still no real consensus regarding the clinical utility of an ER-beta assay, probably because of the lack of standardized methodology, the presence of several ER-beta isotypes (ER-beta1-5, and so on), and, more importantly, the lack of convincing data on whether the ER-beta status provides clinically useful information over what is already provided by the traditional ER-alpha/progesterone receptor (PR) assay. A large and systematic study is needed to address these important issues. PATIENTS AND METHODS: Archival materials of 442 invasive breast cancers from women treated with adjuvant tamoxifen monotherapy and with a long follow-up period (median, 11.1 years) were subjected to immunohistochemical study using three commercially available anti-ER-beta antibodies that detect ER-beta1-3 (ER-betaN), ER-beta1, and ER-betacx (ER-beta2). RESULTS: Positive staining for ER-betaN or ER-beta1 was associated with significantly better survival. By contrast, ER-betacx status did not influence survival. In multivariate analysis, ER-beta1 status emerged as an independent predictor of recurrence and mortality. ER-beta1 status was significantly associated with survival in postmenopausal, but not premenopausal, women. Importantly, ER-beta1 positivity was associated with significantly better survival in patients with ER-alpha-negative/PR-negative or ER-alpha-negative/PR-negative/human epidermal growth factor receptor 2-negative (triple-negative) tumors, which are widely believed to be hormone unresponsive, have poor prognosis, and require chemotherapy. CONCLUSION: Immunohistochemical examination of ER-beta1 in addition to ER-alpha and PR is clinically important in patients with breast cancer treated with tamoxifen monotherapy. Further studies are needed to confirm our findings. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/18669459/Clinical_importance_of_estrogen_receptor_beta_evaluation_in_breast_cancer_patients_treated_with_adjuvant_tamoxifen_therapy_ L2 - https://ascopubs.org/doi/10.1200/JCO.2007.14.2968?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -